,i #aagth ,,congress #b;d ,session ,h4 ,r4 #fehd ,,in ,,the ,,house ,,of ,,representatives ,february #c1 #bjbb,ms4 ,eshoo 7for herself1 ,mr4 ,fitzpatrick1 and ,ms4 ,kelly of ,illinois7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to direct the ,commissioner of ,food and ,drugs to amend certain regulations to increase clinical trial diversity1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,diverse and ,equitable ,participation in ,clinical ,trials ,act or the ,,depict ,act4 #b4 ,premarket reporting of diversity plans for clinical trials and studies 7a7 ,drugs ,the ,commissioner of ,food and ,drugs shall issue regulations revising part #cab of title #ba1 ,code of ,federal ,regulations1 to require sponsors of applications for an exemption for investigational use of a drug to include-- 7#a7 in any such application-- 7,a7 the estimated prevalence in the ,united ,states of the disease or condition for which the drug is being developed or investigated1 disaggregated by demographic subgroup1 where such data is available1 including age group1 sex1 race1 and ethnicity2 7,b7 the sponsor's targets for enrollment in the clinical trial or trials involved1 disaggregated by age group1 sex1 race1 and ethnicity2 7,c7 the rationale for the sponsor's enrollment targets referred to in subparagraph 7,b71 which may include-- 7i7 the estimated prevalence referred to in subparagraph 7,a72 7ii7 what is known about the disease or condition for which the drug is being developed or investigated2 7iii7 any relevant pharmacokinetic or pharmacogenomic data2 7iv7 what is known about the patient population1 including co-morbidities and potential barriers to enrolling diverse participants1 such as patient population size and geographic location2 and 7v7 any other data or information the sponsors deems relevant to selecting appropriate enrollment targets1 disaggregated by demographic subgroup2 and 7,d7 a diversity action plan for how the sponsor will meet such targets1 including demographic-specific outreach and enrollment strategies1 study-site selection1 clinical trial inclusion and exclusion practices1 and any diversity training for trial personnel2 and 7#b7 in an annual report described in section #cab4cc of title #ba1 ,code of ,federal ,regulations-- 7,a7 the sponsor's progress in meeting the targets referred to in paragraph 7#a77;,b72 and 7,b7 if the sponsor does not expect to meet those targets referred to in paragraph 7#a77;,b7-- 7i7 any updates needed to be made to the diversity action plan referred to in paragraph 7#a77;,d7 to meet such targets2 or 7ii7 the sponsor's justification for why the sponsor does not expect to meet such targets1 including-- 7,i7 any factors outside of the sponsor's control1 including a lack of retention of participants2 7,,ii7 any differences in the enrollment targets1 disaggregated by demographic subgroup1 and actual enrollment that the sponsor determines are insignificant in nature2 7,,iii7 potential for selection bias2 and 7,,iv7 information not available to the sponsor at the time such targets were chosen1 but that impacted enrollment of diverse participants4 7b7 ,devices ,the ,commissioner of ,food and ,drugs shall issue regulations revising part #hab of title #ba1 ,code of ,federal ,regulations1 to require sponsors of applications for an exemption for investigational use of a device to include-- 7#a7 in any such application-- 7,a7 a description of the patient population in the ,united ,states expected to use the device1 disaggregated by demographic subgroup1 where such data is available1 including age group1 sex1 race1 and ethnicity2 7,b7 the sponsor's targets for enrollment in the clinical trial or trials involved1 disaggregated by age group1 sex1 race1 and ethnicity2 7,c7 the rationale for the sponsor's enrollment targets referred to in subparagraph 7,b71 which may include-- 7i7 the estimated prevalence referred to in subparagraph 7,a72 7ii7 what is known about the disease or condition for which the drug is being developed or investigated2 7iii7 any relevant pharmacokinetic or pharmacogenomic data2 7iv7 what is known about the patient population1 including co-morbidities and potential barriers to enrolling diverse participants1 such as patient population size and geographic location2 and 7v7 any other data or information the sponsors deems relevant to selecting appropriate enrollment targets1 disaggregated by demographic subgroup2 and 7,d7 a diversity action plan for how the sponsor will meet such targets1 including demographic-specific outreach and enrollment strategies1 study-site selection1 clinical trial inclusion and exclusion practices1 and any diversity training for trial personnel2 and 7#b7 in an annual report described in section #hab4aej of title #ba1 ,code of ,federal ,regulations-- 7,a7 the sponsor's progress in meeting those targets referred to in paragraph 7#a77;,b72 and 7,b7 if the sponsor does not expect to meet those targets referred to in paragraph 7#a77;,b7-- 7i7 any updates needed to be made to the diversity action plan referred to in paragraph 7#a77;,d7 to meet such targets2 or 7ii7 the sponsor's justification for why the sponsor does not expect to meet such targets1 including-- 7,i7 any factors outside of the sponsor's control1 including a lack of retention of participants2 7,,ii7 any differences in the enrollment targets1 disaggregated by demographic subgroup1 and actual enrollment that the sponsor determines are insignificant in nature2 7,,iii7 potential for selection bias2 and 7,,iv7 information not available to the sponsor at the time such targets were chosen1 but that impacted enrollment of diverse participants4 7c7 ,additional clinical trial data ,the ,commissioner of ,food and ,drugs shall issue regulations revising sections #hjg4ib and #had4bj of title #ba1 ,code of ,federal ,regulations1 to require that applications for devices approved under section #eae of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;e7 and devices cleared under section #eaj7k7 of such ,act 7#ba ,u4,s4,c4 #cfj7k77 whose submission includes clinical data-- 7#a7 a description of the patient population in the ,united ,states expected to use the device1 disaggregated by demographic subgroup1 where such data is available1 including age group1 sex1 race1 and ethnicity2 and 7#b7 in summarizing the clinical investigations involving human subjects in such applications1 a description of study subjects by demographic subgroup1 including age group1 sex1 race1 and ethnicity4 7d7 ,deadline for promulgation ,the ,commissioner of ,food and ,drugs shall issue-- 7#a7 any proposed rules required under this section not later than #b years after the date of the enactment of this ,act2 and 7#b7 any final rules required under this section not later than #c years after the date of the enactment of this ,act4 #c4 ,,fda authority to mandate postapproval studies or postmarket surveillance due to insufficient demographic subgroup data 7a7 ,drugs 7#a7 ,in general ,section #eje7o77#c77;,b7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7o77#c77;,b77 is amended by adding at the end the following3 7iv7 ,to provide safety and effectiveness data for the drug involved for a demographic subgroup or subgroups1 if-- 7,i7 the clinical trials conducted in support of the approval of the drug did not meet the applicable targets of enrollment1 as described in section #b of the ,,depict ,act2 and 7,,ii7 in the judgment of the ,secretary1 additional data could inform drug labeling4 4 7#b7 ,waiver ,section #eje7o77#c77;,d7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7o77#c77;,d77 is amended by adding at the end the following3 7iii7 ,clinical trial diversity enrollment ,the ,secretary may not require postapproval studies or postapproval clinical trials for the purpose specified under subparagraph 7,b77iv7 if the sponsor provides to the ,secretary a sufficient justification for not meeting the enrollment targets referred to in such subparagraph1 which may include-- 7,i7 factors outside of the sponsor's control1 such as a lack of retention of participants2 7,,ii7 differences in the enrollment targets1 disaggregated by demographic subgroup1 and actual enrollment that are determined by the ,secretary to be insignificant in nature2 7,,iii7 information not available to the sponsor at the time such enrollment targets were chosen1 but that impacted enrollment of diverse participants2 7,,iv7 potential for selection bias2 and 7,v7 any other reason that the ,secretary determines is sufficient justification4 4 7#c7 ,use of real world evidence ,section #eje7o77#c7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7o77#c77 is amended by adding at the end the following3 7,g7 ,use of real world evidence ,real world evidence 7as defined in section #eje;,f7b77 may be used to support or satisfy the requirements under this paragraph4 4 7b7 ,devices ,section #ebb7;a77#a7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfjl7a77#a77;,a77 is amended-- 7#a7 in subparagraph 7,a7-- 7,a7 in clause 7ii71 by striking or at the end2 7,b7 in clause 7iii77,,ii71 by striking facility4 and inserting facility2 or2 and 7,c7 by adding at the end the following3 7iv7 with respect to which-- 7,i7 clinical studies submitted to support that approval or clearance did not meet the applicable targets of enrollment1 as described in section #b of the ,,depict ,act2 and 7,,ii7 with respect to which a justification described in subparagraph 7,d7 is not provided4 2 and 7#b7 by adding at the end the following3 7,c7 ,use of real world evidence ,real world evidence 7as defined in section #eje;,f7b77 may be used to support or satisfy the requirements under this paragraph4 7,d7 ,clinical trial diversity enrollment ,the ,secretary may not require a manufacturer to conduct postmarket surveillance under subparagraph 7,a7 with respect to a device for the purpose specified in clause 7iv7 of such subparagraph if the manufacturer provides to the ,secretary a sufficient justification for not meeting the enrollment targets referred to in such subparagraph1 which may include-- 7i7 factors outside of the manufacturer's control1 such as a lack of retention of participants2 7ii7 differences in the enrollment targets1 disaggregated by demographic subgroup1 and actual enrollment that are determined by the ,secretary to be insignificant in nature2 7iii7 information not available to the manufacturer at the time such enrollment targets were chosen1 but that impacted enrollment of diverse participants2 7iv7 potential for selection bias2 and 7v7 any other reason that the ,secretary determines is sufficient justification4 4 7c7 ,reports for certain devices ,the ,commissioner of ,food and ,drugs shall issue regulations revising section #had4hd of title #ba1 ,code of ,federal ,regulations1 to require holders of an application approved under section #eae of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;e7 to include in the reports submitted under such section #had4hd1 to the extent possible1 any data not previously submitted under such section #had4hd that may inform the safety and effectiveness of the device involved in underrepresented demographic subgroups4 7d7 ,registry and results data bank inclusion ,section #djb7;j77#a77;,a7 of the ,public ,health ,service ,act 7#bhb7;j77#a77;,a77 is amended-- 7#a7 in clause 7ii7-- 7,a7 in subclause 7,i71 by striking and at the end2 7,b7 in subclause 7,,ii71 by striking the period at the end and inserting 2 and2 and 7,c7 by adding at the end the following3 7,,iii7 postmarket surveillance for any device as required under clause 7iv7 of section #ebb7;a77#a77;,a7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act4 2 and 7#b7 in clause 7iii77,i71 by striking the period at the end and inserting the following3 1 including any postapproval study or postapproval clinical trial for a drug as required under section #eje7o77#c77;,b77iv7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act44 7e7 ,public meeting 7#a7 ,in general ,not later than #bgj days after the date of enactment of this ,act1 the ,secretary1 acting through the ,commissioner of ,food and ,drugs1 and in consultation with drug sponsors1 medical device manufacturers1 patients1 and other stakeholders1 shall convene a public meeting to consider the ways by which-- 7,a7 drug sponsors and medical device manufacturers may disseminate information to the public on clinical trial enrollment demographic data in a timely and accessible manner2 7,b7 drug and device sponsors1 in consultation with the ,commissioner of ,food and ,drugs1 may publicly disseminate information on subgroup analyses conducted by the sponsors in cases where-- 7i7 such data is not sufficient for the purpose of updating drug and device labels2 or 7ii7 such analyses do not show significant differences between demographic subgroups2 and 7,c7 drug and device sponsors1 in consultation with the ,commissioner of ,food and ,drugs1 may collect and publicly disseminate real world evidence that may provide information on the safety and effectiveness of drugs or devices for a demographic subgroup or subgroups4 7#b7 ,report ,not later than #ahj days after the date on which the public meeting is convened under paragraph 7#a71 the ,secretary shall make available on the website of the ,food and ,drug ,administration a report on the topics discussed at such meeting4 ,the report shall include a summary of1 and response to1 recommendations raised in such meeting4 #d4 ,annual report on progress to increase diversity in clinical trials and studies 7a7 ,in general ,beginning not later than #b years after the date of the enactment of this ,act1 and each year thereafter1 the ,secretary of ,health and ,human ,services1 acting through the ,commissioner of ,food and ,drugs1 shall submit to ,congress1 and publish on the public website of the ,food and ,drug ,administration1 a report that addresses progress on increasing diversity in clinical trial and study enrollment4 7b7 ,contents of report ,the report submitted under subsection 7a7 shall include1 with respect to applications for drugs or devices approved or cleared under section #eje1 #eaj7k71 or #eae of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee1 #cfj7k71 or #cfj;e7 or licensed under section #cea of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb7 during the calendar year that immediately precedes the year in which the report is submitted-- 7#a7 an analysis of the extent to which clinical trials conducted with respect to such applications have met the demographic subgroup enrollment targets for clinical trials and studies required by the regulations amended pursuant to section #b and the amendments made by section #c2 7#b7 the frequency with which enrollment targets by demographic subgroup set for a clinical trial conducted under an exemption for investigational use of a drug under section #eje7;i7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7;i77 or section #cea of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb7 or an exemption for investigational use of a device under section #ebj7;g7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;j7g77 do not adequately reflect the incidence in the ,united ,states population of the disease or condition being studied in the clinical trial and a summary of the rationales provided for enrollment targets by demographic subgroup in such cases2 7#c7 a summary of the justifications sponsors provided in the cases where sponsors did not meet the enrollment targets specified pursuant to section #b1 disaggregated by demographic subgroup2 and 7#d7 the ,secretary's recommendations1 as appropriate1 for strategies presented in such diversity plans to attain enrollment targets that should be adopted by sponsors as best practices4 7c7 ,postmarket studies ,beginning #c years after the first instance in which the ,secretary requires the sponsor of an application for a drug or device approved or cleared under section #eje1 #eaj7k71 or #eae of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee1 #cfj7k71 or #cfj;e7 or licensed under section #cea of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb7 to conduct postmarket studies or postmarket surveillance under clause 7iv7 of section #eje7o77#c77;,b7 and clause 7iv7 of section #ebb7;a77#a77;,a7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7as added by subsections 7a7 and 7b7 of section #c71 and each year thereafter1 the report submitted under subsection 7a7 shall also include-- 7#a7 the number of such applications that were required to initiate postmarket studies or surveillance in the previous calendar year under clause 7iv7 of section #eje7o77#c77;,b7 and clause 7iv7 of section #ebb7;a77#a77;,a7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7as added by subsections 7a7 and 7b7 of section #c71 the numbers of such applications that have1 as of the end of the calendar year immediately preceding the year in which the report is submitted1 in-progress postmarket requirements1 and the number of such applications that have completed postmarket requirements for each year1 beginning on the date of the enactment of this ,act2 7#b7 an analysis of the average amount of time for completion of such postmarket requirements1 disaggregated by type of application and type of postmarket requirement2 7#c7 an analysis of how the imposition of such postmarket requirements has impacted the availability of demographic subgroup-specific safety and efficacy data for drugs1 biologics1 and devices2 and 7#d7 the ,secretary's recommendations1 as appropriate1 for additional guidance or postmarket requirements to facilitate the collection and reporting of representative demographic subgroup data in support of applications for the approval or clearance of1 or updates to the labeling of1 drugs and devices under section #eje1 #eaj7k71 or #eae of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee1 #cfj7k71 or #cfj;e7 or licensure of biological products under section #cea of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb74 7d7 ,confidentiality ,nothing in this section shall be construed as authorizing the ,secretary to disclose any information that is a trade secret or confidential information subject to section #eeb7;b77#d7 of title #e1 ,united ,states ,code1 or section #aije of title #ah1 ,united ,states ,code4 #e4 ,public meeting on clinical trial flexibilities initiated in response to ,,covid-#ai pandemic 7a7 ,in general ,not later than #ahj days after the date on which the ,,covid-#ai emergency period ends1 the ,secretary of ,health and ,human ,services shall convene a public meeting to discuss the regulatory flexibilities adopted by the ,food and ,drug ,administration during the ,,covid-#ai emergency period to mitigate disruption of clinical studies and clinical trials1 including flexibilities detailed in the ,march #bjbj guidance entitled ,conduct of ,clinical ,trials of ,medical ,products ,during the ,,covid-#ai ,public ,health ,emergency1 ,guidance for ,industry1 ,investigators1 and ,institutional ,review ,boards1 and any subsequent updates to such guidance4 ,the ,secretary shall invite to such meeting representatives from the pharmaceutical and medical device industries who sponsored clinical trials and clinical studies during the ,,covid-#ai emergency period and organizations representing patients4 7b7 ,topics ,not later than #ij days after the date on which the public meeting under subsection 7a7 is convened1 the ,secretary shall make available on the public website of the ,food and ,drug ,administration a report on the topics discussed at such meeting4 ,such topics shall include discussion of-- 7#a7 the actions drug sponsors took to utilize such regulatory flexibilities and the frequency at which such flexibilities were employed2 7#b7 the characteristics of the sponsors1 trials1 and patient populations impacted by such regulatory flexibilities2 7#c7 a consideration of how regulatory flexibilities to mitigate disruption of clinical trials during the ,,covid-#ai emergency period1 including decentralized clinical trials1 may have affected access to clinical studies and trials for certain patient populations1 especially unrepresented racial and ethnic minorities2 and 7#d7 recommendations for incorporating certain clinical trial disruption mitigation flexibilities into current or additional guidance to improve clinical trial access and enrollment of diverse patient populations4 7c7 ,,covid-#ai emergency period defined ,in this section1 the term ,,covid-#ai emergency period has the meaning given the term emergency period in section #aace7;g77#a77;,b7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acbj;b-#e7;g77#a77;,b774 #f4 ,community engagement and outreach to improve inclusion of underrepresented minorities in clinical trials and research 7a7 ,in general ,the ,secretary of ,health and ,human ,services1 acting through the ,director of the ,national ,institutes of ,health1 shall conduct1 coordinate1 and support activities for purposes of community engagement with1 and outreach to1 underserved communities to facilitate inclusion of underrepresented minorities in clinical research and clinical trials4 7b7 ,activities ,activities conducted1 coordinated1 or supported under this section may be for any of the following purposes3 7#a7 ,developing and disseminating best practices for community engagement and outreach and for inclusive participation in clinical research and trials4 7#b7 ,creating and providing tools and educational resources-- 7,a7 to facilitate adoption of such best practices by researchers and clinical trial sponsors2 and 7,b7 to encourage awareness of1 and participation in1 clinical trials and research among underrepresented minorities4 7#c7 ,engaging community stakeholders in underrepresented racial and ethnic minority communities and fostering partnerships with community-based organizations serving underrepresented racial and ethnical minority populations to encourage participation in clinical trials and research4 7#d7 ,conducting and supporting community engagement research4 7c7 ,supplement1 not supplant ,grants under this subsection shall be used to supplement and not supplant existing initiatives and programs at the ,national ,institutes of ,health to improve diversity in clinical trials and research4 #g4 ,grants to increase the capacity of community health centers to participate in clinical trials and research 7a7 ,in general ,the ,secretary of ,health and ,human ,services1 acting through the ,administrator of the ,health ,resources and ,services ,administration and in consultation with the ,director of the ,national ,institutes of ,health1 shall award grants to1 and enter into cooperative agreements with1 qualified entities to increase capacity at such qualified entities to participate in clinical trials and research by-- 7#a7 enhancing and expanding infrastructure at community health centers to support participation in clinical trials and research1 including information technology improvements and the hiring and training of healthcare personnel1 such as patient navigators and culturally trained site personnel to conduct1 or recruit for1 clinical trials2 7#b7 reimbursing administrative costs and patient care costs incurred by qualified entities in the course of clinical research and trials that are not otherwise reimbursable by existing payers2 and 7#c7 implementing community education and outreach strategies4 7b7 ,qualified entities defined ,in this section1 the term qualified entity means-- 7#a7 rural health clinics1 as defined in section #ahfa7;aa77#b7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciex7aa77#b772 7#b7 federally-qualified health centers described in section #ahfa7;aa77#d77;,b7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciex7aa77#d77;,b772 7#c7 facilities operated by the ,indian ,health ,service1 an ,indian ,tribe1 ,tribal ,organization1 or an ,urban ,indian organization1 as those terms are defined in section #d of the ,indian ,health ,care ,improvement ,act 7#be ,u4,s4,c4 #afjc72 and 7#d7 entities eligible to receive funds under section #ccj of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bed;b74 #h4 ,authorization of appropriations ,there is authorized to be appropriated to carry out this ,act1 #ajj1jjj1jjj for the period of fiscal years #bjbb through #bjbe4